Q4 EPS Estimates for Zimmer Biomet Lifted by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities researchers at Zacks Research raised their Q4 2024 earnings estimates for shares of Zimmer Biomet in a report issued on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.29 for the quarter, up from their previous forecast of $2.26. The consensus estimate for Zimmer Biomet's current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet's Q2 2025 earnings at $2.13 EPS and Q1 2026 earnings at $2.28 EPS.

Other equities analysts have also issued research reports about the company. Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Raymond James lowered their target price on Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Wells Fargo & Company increased their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Oppenheimer lowered their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 15th. Finally, Wolfe Research started coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They issued a "peer perform" rating on the stock. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and an average target price of $123.22.

Zimmer Biomet Price Performance

Shares of NYSE ZBH traded up $0.74 during midday trading on Monday, reaching $110.96. The company's stock had a trading volume of 2,028,435 shares, compared to its average volume of 1,502,395. The company has a market cap of $22.09 billion, a price-to-earnings ratio of 20.95, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The company has a 50 day moving average price of $106.79 and a 200 day moving average price of $109.62.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts' consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same period in the prior year, the business posted $1.65 EPS. The business's revenue for the quarter was up 4.1% compared to the same quarter last year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio is 18.25%.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently made changes to their positions in the company. Dunhill Financial LLC raised its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Zimmer Biomet in the third quarter valued at about $28,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the third quarter valued at about $31,000. Family Firm Inc. bought a new position in Zimmer Biomet during the second quarter worth about $33,000. Finally, Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth about $35,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.